Joshua Mondschein, MD
Radiation Oncology · Nashville, TNNPI 1124239421
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,625 of the $6,161 with a category attached, or 91.3%. Focal Therapeutics, Inc. accounts for 91.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $4,125 and has fallen 94.9% since, to $210 in 2025.
Across 24 payments — averaging $256.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Focal Therapeutics, Inc.$6K
- Novocure Inc.$131
- AstraZeneca$96
- Boston Scientific$84
- Bioprotect Medical, Inc.$49
- Blue Earth Diagnostics$42
- plus $134 from 6 others
What the payments were for
- Consulting fees$5,62591%
- Food & beverage$5369%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Focal Therapeutics, Inc. | 4 | $5,625 |
| Novocure Inc. | 1 | $131 |
| AstraZeneca | 3 | $96 |
| Boston Scientific | 5 | $84 |
| Bioprotect Medical, Inc. | 2 | $49 |
| Blue Earth Diagnostics | 2 | $42 |
| Tactile Systems Technology Inc | 2 | $39 |
| Johnson & Johnson | 1 | $26 |
| Teleflex LLC | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NovoTTF-100L$131
How this compares
$6,161 in reported general payments places this provider in the 85th percentile of 115 radiation oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Nashville
- Han-Chih ChangNashville$66K
- Karen WinkfieldNashville$53K
- James GrayNashville$46K
- John PhillipsNashville$23K
- Casey LipscombNashville$23K
- Andrew KennedyNashville$18K
- Anthony CmelakNashville$16K
- Evan OsmundsonNashville$8K
- Diandra Ayala-PeacockNashville$4K
- Ryan JonesNashville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.